Grunenthal
Grunenthal GmbH, a prominent player in the pharmaceutical industry, is headquartered in Aachen, Germany. Founded in 1888, the company has established a strong presence in Europe, Latin America, and other key regions, focusing on pain management and innovative therapies. Grunenthal is renowned for its commitment to developing unique formulations and delivery systems, particularly in the field of analgesics. With a rich history marked by significant milestones, Grunenthal has pioneered several groundbreaking products that address unmet medical needs. The company’s dedication to research and development has positioned it as a leader in pain relief solutions, earning recognition for its contributions to patient care. Grunenthal continues to strive for excellence, enhancing the quality of life for patients worldwide through its specialised offerings.
DitchCarbon Score
How does Grunenthal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grunenthal's score of 32 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grunenthal's reported carbon emissions
In 2023, Grünenthal reported Scope 1 emissions of approximately 18,137,000 kg CO2e and Scope 2 emissions of about 3,248,000 kg CO2e. This reflects a significant reduction from 2021, where total emissions were approximately 505,821,000 kg CO2e, including 22,638,000 kg CO2e from Scope 1 and 4,882,000 kg CO2e from Scope 2. The company has set ambitious targets to achieve net zero emissions in Scope 1 and 2 by 2030 and 2031, respectively. Grünenthal is also focusing on its Scope 3 emissions, which totalled approximately 478,301,000 kg CO2e in 2021. The company aims to engage key suppliers, responsible for about 67% of its total Scope 3 emissions, to establish emissions targets validated by the Science Based Targets initiative by 2028. These commitments highlight Grünenthal's proactive approach to reducing its carbon footprint and addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | |
|---|---|---|
| Scope 1 | 22,638,000 | 00,000,000 |
| Scope 2 | 4,882,000 | 0,000,000 |
| Scope 3 | 478,301,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grunenthal is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
